Back to Results
First PageMeta Content
Bone fractures / Osteopathies / Amgen / Denosumab / Osteoporosis / Zoledronic acid / Alendronic acid / Aclasta / Bone density / Medicine / Bisphosphonates / Health


Document Date: 2014-10-01 21:56:23

Open Document

File Size: 135,51 KB

Share Result on Facebook

Company

Novartis Pharmaceuticals Australia Pty Ltd / New England Journal / PBAC / /

Country

Australia / /

Currency

USD / /

Event

FDA Phase / /

IndustryTerm

treatment of osteoporosis / zoledronic acid solution / treatment of symptomatic Paget disease / /

MedicalCondition

arrhythmia / established osteoporosis / osteonecrosis / strokes / symptomatic Paget disease / hypertension / disease / glucocorticoid-induced osteoporosis / RACGP osteoporosis / anaphylaxis / postmenopausal osteoporosis / cerebrovascular accidents / ocular disorders / osteoporosis / atrial fibrillation / Paget disease / renal dysfunction / broader primary prevention osteoporosis / acute renal failure / Proposed Therapy Osteoporosis / male osteoporosis / /

MedicalTreatment

intravenous infusion / dialysis / /

Organization

American Medical Association / FDA / View Authority / Listing Requested and PBAC’s View Authority / /

Position

pharmacist / nurse / Trial ID/First author / /

Product

risedronate sodium / alendronate sodium / zoledronic / /

PublishedMedium

New England Journal of Medicine / the DUSC review / Journal of the American Medical Association / /

Technology

x-ray / MRI / dialysis / /

SocialTag